Related Experiment Video
Updated: Jul 16, 2026

Targeted Knockdown of Genes in the Choroid Plexus
Published on: June 16, 2023
Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators
V Wee Yong1, Rana K Zabad, Smriti Agrawal
1Hotchkiss Brain Institute and Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. vyong@ucalgary.ca
Abstract:
The matrix metalloproteinases (MMPs) are implicated in the pathology of multiple sclerosis (MS). This review summarizes the consequences of upregulation of MMP members in MS as well as in an animal model of the disease, experimental autoimmune encephalomyelitis (EAE). The pathogenic roles of MMPs are considered, especially in the transmigration of leukocytes into the CNS. We review the evidence that interferon-beta, an immunomodulator that is commonly used in MS, affects MMP expression in the disease. The potential of minocycline as a therapy in MS, based on its activity as an MMP inhibitor, is discussed. Besides affecting MMPs, minocycline may have other actions that help account for its possible utility in MS.
Insights
Matrix metalloproteinases (MMPs) contribute to multiple sclerosis (MS) pathology by aiding leukocyte migration into the central nervous system. Interferon-beta and minocycline show potential therapeutic effects by modulating MMPs in MS and EAE models.
Area of Science:
- Neuroimmunology
- Biochemistry
Background:
- Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix degradation.
- Elevated MMP levels are observed in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE).
- MMPs play a critical role in the breakdown of the blood-brain barrier, facilitating leukocyte infiltration into the central nervous system (CNS).
Purpose of the Study:
- To review the role of MMPs in the pathology of multiple sclerosis (MS).
- To examine the impact of interferon-beta, a common MS therapeutic, on MMP expression.
- To discuss the therapeutic potential of minocycline, an MMP inhibitor, for MS treatment.
Main Methods:
- Literature review of studies on MMPs in MS and EAE.
- Analysis of research on the effects of interferon-beta on MMPs.
- Evaluation of studies investigating minocycline's mechanism of action and therapeutic efficacy.
Main Results:
- Upregulation of specific MMP members contributes to MS pathogenesis.
- MMPs are crucial for leukocyte transmigration into the CNS in MS and EAE.
- Interferon-beta influences MMP expression in the context of MS.
- Minocycline exhibits MMP inhibitory activity and may offer therapeutic benefits in MS through various mechanisms.
Conclusions:
- MMPs are key players in the inflammatory and neurodegenerative processes of MS.
- Modulating MMP activity presents a potential therapeutic strategy for MS.
- Interferon-beta and minocycline warrant further investigation for their roles in managing MS, considering their effects on MMPs.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Multiple Sclerosis l: Introduction
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Mesenchymal Stem Cells